Bone Mineral Content in Patients with Crohn's Disease: A Longitudinal Study in Patients with Bowel Resections

Staun, Michael; Tjellesen, Lone; Thale, M.; Schaadt, Ole; Jarnum, S.

doi:10.3109/00365529709000199

Cited by 52 publications

(36 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The mean loss at the femoral neck was 2.2% in the group who had undergone a colectomy; there was no change at the lumbar spine and no significant effect from corticosteroids. 26 Another study of 81 patients, 61 with Crohn's disease, who were followed up for a mean period of almost 18 months, reported mean gains of 0.46% at the lumbar spine and 0.06% at the hip. 27 The patients who lost bone, mainly at the hip, were those taking corticosteroids.…”

Section: Discussionmentioning

confidence: 99%

A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease

Bartram

Peaston

Rawlings

et al. 2003

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SummaryBackground : Osteoporosis is a common complication of Crohn's disease.Aim : To study the effect on the bone mineral density of a bisphosphonate (pamidronate) given intravenously, in combination with oral calcium and vitamin D supplements, compared with oral calcium and vitamin D supplements alone.Methods : Seventy‐four patients with Crohn's disease and low bone mineral density at the lumbar spine and/or hip were randomized to receive either a daily dose of 500 mg of calcium with 400 IU of vitamin D alone or in combination with four three‐monthly infusions of 30 mg of intravenous pamidronate over the course of 12 months. The main outcome measure was the change in bone mineral density at the lumbar spine and hip, measured by dual X‐ray absorptiometry, at baseline and 12 months.Results : Both groups gained bone mineral density at the lumbar spine and hip after 12 months. There were significant (P < 0.05) changes in the pamidronate group, with gains of + 2.6%[95% confidence interval (CI), 1.4–3.0] at the spine and + 1.6% (95% CI, 0.6–2.5) at the hip, compared with gains of + 1.6% (95% CI, − 0.1–3.2) and + 0.9% (95% CI, − 0.4–2.1) at the spine and hip, respectively, in the group taking vitamin D and calcium supplements alone.Conclusions : In patients with Crohn's disease and low bone mineral density, intravenous pamidronate significantly increases the bone mineral density at the lumbar spine and hip.

show abstract

Section: Discussionmentioning

confidence: 99%

A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease

Bartram

Peaston

Rawlings

et al. 2003

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…The role of glucocorticoids in the pathogenesis of osteoporosis especially in IBD is complex. Whilst some studies have shown a clear relationship between lifetime corticosteroid dose in IBD and vertebral fracture rate (4,52) or low BMD (14,16,43,45,47) other studies have suggested that BMD is unrelated to corticosteroid use (25,26,27,28,29). Our study did not fi nd a negative relationship between the cumulative or total lifetime dose of glucocorticoids and BMD, moreover almost 23 % of patients with osteopenia/osteoporosis have never used glucocorticoids during their disease.…”

Section: Discussionmentioning

confidence: 99%

“…Although there is evidence that long-term corticosteroid therapy reduces the BMD (9,12,13,14,15,22,23,24), some of stud-ies have suggested that BMD in IBD is unrelated to corticosteroid use (25,26,27,28,29). Considering the fact that newly diagnosed patients already have a reduced bone mineral density (BMD), there is a strong case for suggesting that demineralization in patients with IBD occurs primarily as a consequence of intestinal infl ammation.…”

mentioning

confidence: 99%

The prevalence and risk factors for osteoporosis in patients with inflammatory bowel disease

Miznerova

Hlavatý²,

Koller³

et al. 2013

BLL

View full text Add to dashboard Cite

Abstract:Aim: Osteoporosis is a known chronic complication of infl ammatory bowel diseases (IBD). The aim of our study was to describe the prevalence of reduced bone mineral density (BMD) in IBD patients and to identify crucial risk factors for osteoporosis. Methods: The cohort consisted of 76 IBD patients, 40 with Crohn's disease (CD) and 36 with ulcerative colitis (UC). Clinical characteristics of every patient were recorded, i.e. age, sex, duration of the disease, clinical behavior, location of disease according to Montreal classifi cation, surgeries, steroid medication, sIBDQ, and smoking habits. We examined the serum 25-hydroxyl vitamin D3 (25-OHD3) in each patient. The BMD was determined by dual-energy X-ray absorptiometry (DXA) at the lumbar spine and femoral neck. Results: Osteoporosis was documented in 10 IBD patients (13.2 %), while osteopenia in 35 of them (46.1 %). Patients with CD have signifi cantly lower femoral Z score than patients with UC. Femoral Z score was strongly associated with disease duration, and in CD patients suffering from stricturing form, with ileic or ileocolic location and history of proctocolectomy or total colectomy. Patients with osteoporosis had a signifi cantly lower level of 25-OHD3 than patients with normal BMD. Conclusion: Patients with long disease duration and those suffering from stricturing form of CD with ileic/ileocolic location and history of proctocolectomy/total colectomy are at higher risk of developing osteoporosis than other IBD patients. The high proportion of osteopenia/osteoporosis in our study underlines the importance of BMD measurement in all IBD patients as a base for initiating the appropriate treatment (Tab. 1, Fig. 3

show abstract

“…In the first year, usually a rapid decrease is observed. Bone density change rate is found to be higher in patients with low baseline levels (52). Determined mean annual changes in BMD are between 0% to 3% (8, 12, 23, 45, 50 -56).…”

Section: Annual Bone Density Change Rates In Crohn's Diseasementioning

confidence: 92%

When and how frequently DEXA should be performed for the diagnosis and follow-up of osteoporosis in Crohn’s disease?

Kabaçam

Tezel²

2010

Turk J Gastroenterol

View full text Add to dashboard Cite

show abstract

Bone Mineral Content in Patients with Crohn's Disease: A Longitudinal Study in Patients with Bowel Resections

Abstract: At inclusion the BMC of the spine and femoral neck was low in patients with Crohn's disease. During the study significant bone loss was only demonstrated in the femoral neck. BMC or rate of change in BMC was not related to treatment with steroids or length of the resected small intestine.

Cited by 52 publications

References 14 publications

A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease

A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease

The prevalence and risk factors for osteoporosis in patients with inflammatory bowel disease

When and how frequently DEXA should be performed for the diagnosis and follow-up of osteoporosis in Crohn’s disease?

Contact Info

Product

Resources

About